26.08.2016
Zugemailt von: Baader Bank (BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)
We downgrade SBO from Hold to Sell. We keep our target price unchanged at EUR 46. We calculate with an oil price between USD 45 and USD 55 for the next two years. This implies that the SBO customers will remain reluctant when it comes to new orders in the coming quarters. But after winding down inventories and keeping up production, they have to order again. We expect that this will start during 1H17.
The 1H16 report indicated no improvement. In the related call the management was very cautious regarding the development during the rest of the year. The order intake shows almost no sign of any improvement, so far. 1H16 sales reached EUR 88mn (53% down yoy) despite the integration of Downhole. The operating EBIT came in with EUR -31.2mn vs. EUR 19.3mnthe year before. Order intake was down 28.4% in 1H16.
Positive operating FCF. Despite the massive decline of the top line and a negative operating result, SBO was able to generate a positive operating FCF of EUR 18.5mn. The operating FCF was driven by a further reduction of operating costs, lower net working capital and the cut of capex to an absolute minimum. The reported FCF was negative with EUR -76mn because of the acquisition of Downhole.
Valuation: Our target price of EUR 46 is based on a DCF model. The underlying assumption is a slight recovery of the market during 2017. And with the reduced operating leverage and a higher share of the more profitable oilfield equipment segment, we modelled that SBO is able to generate EBIT margins above 20% from 2019 onwards. When it comes to multiples based on consensus estimates, the 2017 figures remain outstandingly high with an EV/EBITDA of ~11 and a P/E of ~38.
Risk to our recommendation. Any decision of the OPEC to cut production or any other political scenario which drives the oil price well above the USD 50 line might be supportive for the SBO share price.
Aktien auf dem Radar:Immofinanz, CA Immo, DO&CO, Warimpex, Flughafen Wien, Marinomed Biotech, VIG, Porr, EVN, RBI, Uniqa, Telekom Austria, AT&S, Rosenbauer, ams-Osram, FACC, Stadlauer Malzfabrik AG, Wolford, Zumtobel, Oberbank AG Stamm, BKS Bank Stamm, Kapsch TrafficCom, Agrana, Amag, Erste Group, Österreichische Post, Polytec Group, S Immo, Wienerberger, Rheinmetall, SAP.
(BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)125104
inbox_baader_stuft_sbo_auf_sell_weist_aber_auch_auf_aufwartsrisiken_hin
Croma
Croma Pharma® ist ein österreichisches Familienunternehmen mit Sitz in Leobendorf. Das Unternehmen ist auf die industrielle Fertigung von Hyaluronsäure-Spritzen spezialisiert und zählt in diesem Bereich europaweit zu den führenden Experten. Das Unternehmen setzt mit eigenen Marken auf die Wachstumssparte der minimalinvasiven ästhetischen Medizin.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/goboersewien
26.08.2016, 3209 Zeichen
26.08.2016
Zugemailt von: Baader Bank (BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)
We downgrade SBO from Hold to Sell. We keep our target price unchanged at EUR 46. We calculate with an oil price between USD 45 and USD 55 for the next two years. This implies that the SBO customers will remain reluctant when it comes to new orders in the coming quarters. But after winding down inventories and keeping up production, they have to order again. We expect that this will start during 1H17.
The 1H16 report indicated no improvement. In the related call the management was very cautious regarding the development during the rest of the year. The order intake shows almost no sign of any improvement, so far. 1H16 sales reached EUR 88mn (53% down yoy) despite the integration of Downhole. The operating EBIT came in with EUR -31.2mn vs. EUR 19.3mnthe year before. Order intake was down 28.4% in 1H16.
Positive operating FCF. Despite the massive decline of the top line and a negative operating result, SBO was able to generate a positive operating FCF of EUR 18.5mn. The operating FCF was driven by a further reduction of operating costs, lower net working capital and the cut of capex to an absolute minimum. The reported FCF was negative with EUR -76mn because of the acquisition of Downhole.
Valuation: Our target price of EUR 46 is based on a DCF model. The underlying assumption is a slight recovery of the market during 2017. And with the reduced operating leverage and a higher share of the more profitable oilfield equipment segment, we modelled that SBO is able to generate EBIT margins above 20% from 2019 onwards. When it comes to multiples based on consensus estimates, the 2017 figures remain outstandingly high with an EV/EBITDA of ~11 and a P/E of ~38.
Risk to our recommendation. Any decision of the OPEC to cut production or any other political scenario which drives the oil price well above the USD 50 line might be supportive for the SBO share price.
Was noch interessant sein dürfte:
Inbox: Weg frei für ein bisschen mehr conwert an der Wiener Börse
Inbox: US-Aktienmärkte abwartend – Monsanto und Pfizer im Fokus – Minenwerte schwach
Inbox: KTM Industries stark und mit noch stärkerem Ausblick
Inbox: Sanochemia macht Gewinn und ist recht optimistisch
Inbox: SRC sieht S Immo Aktie deutlich zweistellig
ATX verliert am Donnerstag 0,6 Prozent und die 2300er-Marke; SBO stürzt um weitere 4 Prozent ab
Inbox: Wie QE die Preise verzerrt oder frei vs. kommunistisch
Börsenradio Live-Blick, Mo. 12.8.24: DAX fester in KW33, wichtige Chartmarke, Hannover Re nach Zahlen top, Baader mag SAP
Aktien auf dem Radar:Immofinanz, CA Immo, DO&CO, Warimpex, Flughafen Wien, Marinomed Biotech, VIG, Porr, EVN, RBI, Uniqa, Telekom Austria, AT&S, Rosenbauer, ams-Osram, FACC, Stadlauer Malzfabrik AG, Wolford, Zumtobel, Oberbank AG Stamm, BKS Bank Stamm, Kapsch TrafficCom, Agrana, Amag, Erste Group, Österreichische Post, Polytec Group, S Immo, Wienerberger, Rheinmetall, SAP.
Croma
Croma Pharma® ist ein österreichisches Familienunternehmen mit Sitz in Leobendorf. Das Unternehmen ist auf die industrielle Fertigung von Hyaluronsäure-Spritzen spezialisiert und zählt in diesem Bereich europaweit zu den führenden Experten. Das Unternehmen setzt mit eigenen Marken auf die Wachstumssparte der minimalinvasiven ästhetischen Medizin.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab.
Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.
Newsletter abonnieren
Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)
per Newsletter erhalten
AT0000A3C5D2 | |
AT0000A2UVV6 | |
AT0000A2SKM2 |
Saucony Endorphin Speed VS Saucony Endorphin Pro (vom Profi getestet)
Teste die neuesten Laufschuh-Modelle im WEMOVE Runningstore ► www.wemove.at Diesmal teste ich den Saucony Endorphin Speed sowie den Saucony Endorphin Pro im direkten Vergleich. Welcher Schuh ist f...
Max Zerrahn
Musical Chairs
2024
White Belt Publishing
Sergio Castañeira
Limbo
2023
ediciones anómalas
Jerker Andersson
Found Diary
2024
Self published
Dominic Turner
False friends
2023
Self published
Kjell-Ake Andersson & Mikael Wiström
Gruvarbetare i Wales
1977
Trydells